Research Advances

A new study has identified cellular inhibitor of apoptosis protein 1 (cIAP1), encoded by the BIRC2 gene, as a potential tumor suppressor in Ewing sarcoma, a rare and aggressive pediatric cancer driven by EWSR1::FLI1 fusion proteins. Researchers analyzed gene activity across multiple Ewing sarcoma cell lines and patient datasets, finding that higher cIAP1 levels were […]

A new study found that the protein KRT19 may play a major role in helping gastric cancer spread. Researchers discovered that KRT19 does more than provide structural support inside cells. Instead, it can move into the cell nucleus and activate signals that increase cancer cell movement and invasion. The study showed that KRT19 levels were

A major international study has created the first large-scale genetic map of cancer in domestic cats, offering new insights that may benefit both veterinary and human medicine. Researchers analyzed tumor samples from nearly 500 cats across five countries and discovered that feline cancers share many of the same cancer-driving genes seen in humans and dogs,

A new study has identified Toll-Like Receptor 2 (TLR2) as a major driver of immune resistance in pancreatic ductal adenocarcinoma (PDAC), one of the deadliest forms of cancer. Researchers found that TLR2 prevents cancer-fighting T cells from entering tumors, helping explain why pancreatic cancer often resists immunotherapy. Using mouse models and human tumor data, scientists

A real-world study suggests that GLP-1 receptor agonists, including semaglutide, may significantly reduce the risk of cancer metastasis in patients with early-stage solid tumors. Researchers analyzed data from over 10,000 patients with stage I–III cancers and compared those taking GLP-1 drugs with matched patients using DPP-4 inhibitors. Results showed a 31% to 50% reduction in

mRNA-based cancer therapies work by delivering genetic instructions that tell cells to produce specific proteins without changing DNA, reducing risks linked to genome integration. However, mRNA is unstable and difficult to deliver into cells because it degrades quickly and cannot easily cross cell membranes. To overcome this, scientists use lipid nanoparticles (LNPs) that protect mRNA

A study published in Nature has identified a key epigenetic mechanism that drives resistance to 5-fluorouracil (5-FU) in colorectal cancer. Researchers found that increased activity of the enzyme EHMT2 leads to suppression of a tumor-suppressor gene called PPM1B, allowing cancer cells to survive chemotherapy and continue growing. The study showed that EHMT2 modifies gene expression

Researchers analyzing biomarkers from the phase 2 SunRISe-4 Trial found that high tumor mutational burden (TMB), genomic disease burden (GDB), and PD-L1 expression were linked to better pathologic overall response in patients with muscle-invasive bladder cancer (MIBC) receiving cisplatin-free neoadjuvant therapy. The study evaluated tissue and urine samples from 88 patients treated with a sustained

Researchers have found that a repurposed drug combination of disulfiram and copper may help overcome chemotherapy resistance in pancreatic cancer, one of the most lethal cancer types. The study focuses on pancreatic ductal adenocarcinoma, where resistance to the chemotherapy drug 5-fluorouracil (5-FU) often limits the effectiveness of standard treatment regimens like FOLFIRINOX. Scientists discovered that

Researchers are developing a new nanotechnology-based treatment strategy for pancreatic cancer that aims to overcome two major barriers: the tumor’s dense protective tissue and its ability to suppress the immune system. The approach uses smart nanomaterials designed to trigger a form of cancer cell death called ferroptosis, which depends on iron and causes toxic damage